fda tirzepatide compound update Important Update: Compounded Phasing Out! FDA Update: Current Guidelines for

As expected, the AEs were mainly gastrointestinal and, while one subject withdrew from the study because of nausea, the majority of events were mild, and all were mild to moderate, in severity

Diarrhea or Constipation: As your digestive rhythm changes, you may experience loose stools or find it difficult to pass bowel movements

Patients with diabetes or prediabetes should monitor blood glucose closely Theoretical cancer concern: improved IGF-1 has been associated with certain cancer risks in epidemiological studies

Therefore, future studies should further explore these differences to ensure the applicability and safety of tirzepatide in different populations, and consider the influence of lifestyle factors on efficacy to optimize the therapeutic effect in different populations